OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

SANDOZ GROUP AG/  CH1243598427  /

Turquoise
7/26/2024  5:19:45 PM Chg. +0.89 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
35.99CHF +2.52% 12,534
Turnover: 448,990.64		 -Bid Size: - -Ask Size: - 16.26 bill.CHF - -
GlobeNewswire 7/1 FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire 5/22 Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire 5/7 Sandoz reports first quarter 2024 sales
GlobeNewswire 4/30 Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire 4/30 Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire 4/22 Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire 3/21 Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire 3/13 Sandoz reports fourth quarter 2023 sales and full-year 2023 results
GlobeNewswire 3/5 Sandoz receives FDA approval for first and only denosumab biosimilars
GlobeNewswire 3/5 Sandoz announces nominations to the Board of Directors and leadership change
GlobeNewswire 3/4 Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire 2/29 Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire 2/1 Sandoz announces changes in the Board of Directors
GlobeNewswire 1/31 Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire 1/22 Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire 11/21/2023 Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...
GlobeNewswire 11/10/2023 Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center ...
GlobeNewswire 11/8/2023 Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
GlobeNewswire 10/26/2023 Sandoz successfully issues CHF 750 million in inaugural bonds
GlobeNewswire 10/24/2023 Sandoz reports year-to-date sales for the first nine months of 2023
GlobeNewswire 10/4/2023 OTC Markets Group Welcomes Sandoz Group AG to OTCQX
TeleTrader 10/4/2023 Sandoz seals spin-off from Novartis, starts trading
GlobeNewswire 10/4/2023 Sandoz enters new era as standalone global leader and European champion in generic and biosimilar me...